JP2023516067A5 - - Google Patents
Info
- Publication number
- JP2023516067A5 JP2023516067A5 JP2022552528A JP2022552528A JP2023516067A5 JP 2023516067 A5 JP2023516067 A5 JP 2023516067A5 JP 2022552528 A JP2022552528 A JP 2022552528A JP 2022552528 A JP2022552528 A JP 2022552528A JP 2023516067 A5 JP2023516067 A5 JP 2023516067A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- heavy chain
- light chain
- seq
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984139P | 2020-03-02 | 2020-03-02 | |
| US62/984,139 | 2020-03-02 | ||
| US202063084138P | 2020-09-28 | 2020-09-28 | |
| US63/084,138 | 2020-09-28 | ||
| PCT/US2021/020511 WO2021178430A2 (en) | 2020-03-02 | 2021-03-02 | Chimeric antigen receptors and related methods and compositions for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516067A JP2023516067A (ja) | 2023-04-17 |
| JP2023516067A5 true JP2023516067A5 (cg-RX-API-DMAC7.html) | 2024-03-06 |
| JP7834345B2 JP7834345B2 (ja) | 2026-03-24 |
Family
ID=77613112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552528A Active JP7834345B2 (ja) | 2020-03-02 | 2021-03-02 | がんの処置のためのキメラ抗原受容体ならびに関連した方法および組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12595311B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4114861A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7834345B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220149606A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115551891A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021232512A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3174575A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021178430A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| KR20250067749A (ko) * | 2023-11-07 | 2025-05-15 | 주식회사 박셀바이오 | EphA2를 타겟하는 개선된 특성을 갖는 친수성 모노바디 및 이를 포함하는 다중특이적 키메라 항원 수용체 및 조작된 면역세포 |
| WO2026096570A1 (en) * | 2024-10-30 | 2026-05-07 | Pluto Immunotherapeutics, Inc. | Hybrid anti-cd20 car t cell therapy for the treatment of autoimmune diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050037420A1 (en) * | 2001-09-14 | 2005-02-17 | Mei-Yun Zhang | Immunoglobulin having particular framework scaffold and methods of making and using |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| AU2017235657B2 (en) | 2016-03-18 | 2022-07-21 | Fred Hutchinson Cancer Center | Compositions and methods for CD20 immunotherapy |
| US20190112380A1 (en) | 2016-03-29 | 2019-04-18 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| CN117298260A (zh) | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
| EP3529268B1 (en) | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| WO2018200582A1 (en) | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Chimeric antibody/t-cell receptor constructs and uses thereof |
| CA3069527A1 (en) | 2017-07-12 | 2019-01-17 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treatment of cancers harboring an h3k27m mutation |
| BR112020005938A2 (pt) | 2017-09-27 | 2020-11-17 | University Of Southern California | célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso |
| AU2020232789B2 (en) * | 2019-03-06 | 2026-04-09 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with self-driving chimeric antigen receptors |
| IL305175A (en) * | 2021-02-19 | 2023-10-01 | Angeles Therapeutics Inc | Single-chain and multi-chain synthetic antigen receptors for diverse immune cells |
-
2021
- 2021-03-02 KR KR1020227034525A patent/KR20220149606A/ko active Pending
- 2021-03-02 AU AU2021232512A patent/AU2021232512A1/en active Pending
- 2021-03-02 WO PCT/US2021/020511 patent/WO2021178430A2/en not_active Ceased
- 2021-03-02 CN CN202180032322.2A patent/CN115551891A/zh active Pending
- 2021-03-02 EP EP21764636.3A patent/EP4114861A4/en active Pending
- 2021-03-02 JP JP2022552528A patent/JP7834345B2/ja active Active
- 2021-03-02 US US17/908,703 patent/US12595311B2/en active Active
- 2021-03-02 CA CA3174575A patent/CA3174575A1/en active Pending
-
2024
- 2024-10-15 US US18/915,927 patent/US12479923B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI899054B (zh) | 治療癌症及增強t細胞重定向治療劑之功效的方法(一) | |
| CN112673022B (zh) | 针对cd33的单结构域抗体及其构建体 | |
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| US12534532B2 (en) | CLL1-targeting antibody and application thereof | |
| JP2022002546A (ja) | 細胞 | |
| IL312206A (en) | Preparations and methods for selective protein expression | |
| JP2022548778A5 (cg-RX-API-DMAC7.html) | ||
| TW201904997A (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| CN116829194A (zh) | 用于工程化细胞疗法的靶向细胞因子构建体 | |
| CA3131016A1 (en) | Multifunctional molecules that bind to calreticulin and uses thereof | |
| US20230257475A1 (en) | Multispecific chimeric antigen receptors and uses thereof | |
| JP2025066746A (ja) | 抗adam12抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法 | |
| WO2023202280A1 (zh) | 抗B7H6的scFv抗体、其编码基因及其应用 | |
| JP2024105603A (ja) | CARライブラリおよびscFvの製造方法 | |
| KR20210111244A (ko) | 태반-유래 동종이계 car-t 세포 및 이의 용도 | |
| WO2023217062A1 (zh) | 一种嵌合抗原受体及其应用 | |
| WO2025140265A1 (en) | Combination of chimeric antigen receptor and dap10 in cell therapy | |
| CN117957246A (zh) | Mog结合蛋白和其用途 | |
| TW202309294A (zh) | 病毒載體生產系統 | |
| TW202434636A (zh) | 抗原結合域及其使用方法 | |
| JP2022546590A5 (cg-RX-API-DMAC7.html) | ||
| JP2025540909A (ja) | 免疫療法のためのcd3発現及びキメラ抗原受容体の遮断 | |
| KR20260036568A (ko) | 세포 면역 요법용 조성물, 및 방법 | |
| WO2024151213A2 (en) | Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies |